BRCA-mutant pancreatic ductal adenocarcinoma

[1]  Haroon,et al.  A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes , 2022, Medicine.

[2]  B. Karlan,et al.  Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  Man Yu,et al.  A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report , 2021, BMC medical genomics.

[4]  W. Kraus,et al.  Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance , 2021, Experimental & molecular medicine.

[5]  J. Baranda,et al.  Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review , 2020, Journal of pancreatic cancer.

[6]  P. Philip,et al.  Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma , 2020, ESMO Open.

[7]  J. Armenia,et al.  A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. Greenwood,et al.  A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer , 2020, Clinical Cancer Research.

[9]  M. Guo,et al.  Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer , 2020, Cancer science.

[10]  S. Bates,et al.  BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects , 2020, Cancer management and research.

[11]  Xue Wu,et al.  Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation. , 2020, American journal of translational research.

[12]  S. Im,et al.  PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation , 2020, Cancers.

[13]  A. Chen,et al.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Nathanson,et al.  Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation , 2019, British Journal of Cancer.

[15]  R. Iyer,et al.  Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications , 2019, Cancers.

[16]  K. Nathanson,et al.  Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. , 2019, JCO precision oncology.

[17]  M. Scartozzi,et al.  New therapeutic targets in pancreatic cancer. , 2019, Cancer treatment reviews.

[18]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[19]  J. Berlin,et al.  Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. , 2019, Journal of Clinical Oncology.

[20]  J. Marshall,et al.  Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC). , 2019, Journal of Clinical Oncology.

[21]  R. Pilarski.  The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[22]  E. Vasile,et al.  The Italian Rare Pancreatic Exocrine Cancer Initiative , 2019, Tumori.

[23]  M. Goggins,et al.  Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[25]  N. Tung,et al.  Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma , 2018, Cancer.

[26]  W. Hahn,et al.  Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer , 2018, Genetics in Medicine.

[27]  E. Vasile,et al.  Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis , 2018, Pancreas.

[28]  R. Berger,et al.  Recapitulating the clinical scenario of BRCA‐associated pancreatic cancer in pre‐clinical models , 2018, International journal of cancer.

[29]  Raymond M. Moore,et al.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer , 2018, JAMA.

[30]  Masakazu Yamamoto,et al.  Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma , 2018, Scientific Reports.

[31]  A. Biankin,et al.  Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. , 2018, JCO precision oncology.

[32]  A. Ashworth,et al.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial , 2018, Nature Medicine.

[33]  J. Cameron,et al.  BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. , 2018, Journal of the American College of Surgeons.

[34]  K. Nathanson,et al.  Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. , 2018, JCO precision oncology.

[35]  J. Barkun,et al.  Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. , 2018, JCO precision oncology.

[36]  D. Zhang,et al.  CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma , 2018, Biological Research.

[37]  W. Chung,et al.  The impact of hereditary cancer gene panels on clinical care and lessons learned , 2017, Cold Spring Harbor molecular case studies.

[38]  Masaya Suenaga,et al.  Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Melisi,et al.  Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? , 2017, Critical reviews in oncology/hematology.

[40]  David C. Smith,et al.  Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. , 2017, Cancer discovery.

[41]  J. Valle,et al.  Germline mutations in pancreatic cancer and potential new therapeutic options , 2017, Oncotarget.

[42]  Kan Zhai,et al.  BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population , 2017, Oncotarget.

[43]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[44]  A. Biankin,et al.  BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer , 2017, British Journal of Cancer.

[45]  E. Vasile,et al.  Multimodal treatment of resectable pancreatic ductal adenocarcinoma. , 2017, Critical reviews in oncology/hematology.

[46]  S. Gallinger,et al.  Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer , 2017, British Journal of Cancer.

[47]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[48]  K. Offit,et al.  Identification of germline genetic mutations in patients with pancreatic cancer , 2015, Cancer.

[49]  Minjeong Park,et al.  Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269‐275. , 2015, Cancer.

[50]  D. Hedley,et al.  Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  C. Walsh.  Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. , 2015, Gynecologic oncology.

[52]  Masakazu Yamamoto,et al.  Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas , 2015, Scientific Reports.

[53]  G. Petersen,et al.  Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. , 2015, Gastroenterology.

[54]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[55]  Randall W Burt,et al.  ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes , 2015, The American Journal of Gastroenterology.

[56]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Michele L Cote,et al.  BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study , 2014, Genetics in Medicine.

[58]  P. Ghiorzo.  Genetic predisposition to pancreatic cancer. , 2014, World journal of gastroenterology.

[59]  R. Gershoni-baruch,et al.  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.

[60]  Lincoln D. Stein,et al.  Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer , 2013, Human Genomics.

[61]  P. Møller,et al.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers , 2012, British Journal of Cancer.

[62]  Douglas F. Easton,et al.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. , 2012, JAMA.

[63]  K. Offit,et al.  Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer , 2012, Cancer.

[64]  A. Klein.  Genetic susceptibility to pancreatic cancer , 2012, Molecular carcinogenesis.

[65]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2011, Familial Cancer.

[66]  E. Kuipers,et al.  Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated , 2011, European Journal of Human Genetics.

[67]  M. Robson,et al.  An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. , 2011, The oncologist.

[68]  L. Kadouri,et al.  Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy , 2011, Cancer biology & therapy.

[69]  Eric D Wieben,et al.  Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling , 2011, European Journal of Human Genetics.

[70]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[71]  B. Lau,et al.  Importance of Age of Onset in Pancreatic Cancer Kindreds , 2010, Journal of the National Cancer Institute.

[72]  S. Narod,et al.  Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[74]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[75]  Laura H. Tang,et al.  BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[77]  R. Berardi,et al.  Pancreatic cancer: progress in cancer therapy. , 2008, Critical reviews in oncology/hematology.

[78]  R. Berardi,et al.  COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin , 2007, American journal of clinical oncology.

[79]  Mariza de Andrade,et al.  The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[80]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[81]  B. Friedenson.  BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. , 2005, MedGenMed : Medscape general medicine.

[82]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[83]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[84]  R. Berardi,et al.  New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols. , 2005, JOP : Journal of the pancreas.

[85]  K. Welte,et al.  Down-Regulation of BRCA1 in Chronic Pancreatitis and Sporadic Pancreatic Adenocarcinoma , 2004, Clinical Cancer Research.

[86]  J. Satagopan,et al.  Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. , 2004, Journal of the National Cancer Institute.

[87]  A. Ziegler,et al.  BRCA2 germline mutations in familial pancreatic carcinoma. , 2003, Journal of the National Cancer Institute.

[88]  Alan Ashworth,et al.  The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. , 2002, Trends in molecular medicine.

[89]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[90]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[91]  P. Maisonneuve,et al.  Epidemiologic and etiologic factors of pancreatic cancer. , 2002, Hematology/oncology clinics of North America.

[92]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[93]  S. Gallinger,et al.  Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. , 2000, Cancer research.

[94]  W. Foulkes,et al.  Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. , 1999, Journal of the National Cancer Institute.

[95]  I. Lerer,et al.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. , 1997, American journal of human genetics.

[96]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[97]  H. Burstein,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[98]  Laura H. Tang,et al.  Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. , 2018, European journal of cancer.

[99]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[100]  M. Beattie,et al.  Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations , 2008, Familial Cancer.

[101]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[102]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[103]  M M Grajower,et al.  Familial pancreatic cancer. , 1983, Annals of internal medicine.